Articles tagged ”GalactEXO”
Understanding the Functional Impact of Monoclonal Antibody Asymmetrical Fc N-Glycan Pairs using SmartEnzymes™
Scientists at Boehringer Ingelheim and collaborators have developed a novel method to generate antibodies with defined asymmetrical Fc glycoforms and evaluate their Fc receptor (FcγRs) binding properties. Combining enzymatic digestion and redox-mediated Fc recombination, Fc fragments with specific glycan pairings could be generated and their Fc receptor binding analyzed by surface plasmon resonance (SPR) spectroscopy.
Read more »
[GenovisWebinar!] 🤩 Unlocking Antibody Insights with Regeneron: SmartEnzymes™ in Action!
We are thrilled to welcome Xin Wang from Regeneron Pharmaceuticals to showcase how the reliability and robust performance of Genovis’ SmartEnzymes have enabled their subunit HILIC-MS method to be successfully applied across multiple Regeneron programs and commercial mAbs.
Characterization of SARS-CoV-2 Receptor-Binding Domains using SmartEnzymes™
Scientists at Leiden University Medical Center (LUMC) present a multilevel mass spectrometry approach using SmartEnzymes for in-depth characterization of mammalian SARS-CoV-2 receptor-binding (RBD) domains.
The COVID-19 disease caused by the SARS-CoV-2 virus has affected more that 100 million individuals in the ongoing pandemic. The enveloped RNA corona virus contains three structural proteins in the membrane, including the heavily glycosylated spike protein carrying 22 N-glycosylation sites. The spike protein in turn consists of two subunits, S1 and S2, where the receptor-binding domain (RBD) of S1 directly interacts with the ACE2 receptor in the human respiratory tract and facilitates host cell entry. Considering the relevance of RBD glycosylation on ACE2 binding and recognition by neutralizing antibodies, the use of well-characterized S proteins is essential for continued research and development of diagnostic tools and vaccines.